# US 2017/0253654 A1 · Anti-pd-l1 antibodies and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253654 A1
- Document ID: US20170253654A1
- Status: Published application
- Kind: A1
- Application number: 15/454,959
- Filed: 2017-03-09
- Published: 2017-09-07
- Earliest claimed: 2011-11-28
- Assignees: Merck Patent GmbH
- Applicants: Merck Patent GmbH
- Inventors: Horacio G. Nastri; Christel Iffland; Olivier Leger; Qi An; Mark Cartwright; Sean D. McKenna
- Web page: https://patentgrep.com/patent/US20170253654A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 31/282: Platinum compounds
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 39/001102: {Receptors, cell surface antigens or cell surface determinants}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/10: of the bladder
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.

## Claims

### Claim at position 1

1-75. (canceled)

### Claim 76

A method of treating cancer comprising administering to a subject in need thereof an effective amount of an anti-PD-L1 antibody which induces antibody dependent cell-mediated cytotoxicity (ADCC).

### Claim at position 3

77-92. (canceled)

### Claim 93 (depends on 76)

The method of claim 76, wherein the constant region of the anti-PD-L1 antibody is IgG1.

### Claim 94 (depends on 76)

The method of claim 76, wherein the anti-PD-L1 antibody comprises:
a light chain variable region; and
a heavy chain variable region comprising HVR-H1, HVR-H2, and HVR-H3 sequences, wherein:
(a)
(SEQ ID NO: 1)
the HVR-H1 sequence is X1YX2MX3;
(b)
(SEQ ID NO: 2)
the HVR-H2 sequence is SIYPSGGX4TFYADX5VKG;
and
(c)
(SEQ ID NO: 3)
the HVR-H3 sequence is IKLGTVTTVX6Y;
and further wherein:
X1 is K, R, T, Q, G, A, W, M, I or S;
X2 is V, R, K, L, M or I;
X3 is H, T, N, Q, A, V, Y, W, F or M;
X4 is F or I;
X5 is S or T; and
X6 is E or D.

### Claim 95 (depends on 94)

The method of claim 94, wherein:
(a) X1 is M, I or S; X2 is R, K, L, M or I; X3 is F or M; X4 is F or I; X5 is S or T; and X6 is E or D;
(b) X1 is M, I or S; X2 is L, M or I; X3 is F or M; X4 is I; X5 is S or T; and X6 is D; or
(c) X1 is S; X2 is I; X3 is M; X4 is I; X5 is T; and X6 is D.

### Claim 96 (depends on 94)

The method of claim 94, wherein the heavy chain variable region comprises heavy chain framework sequences HC-FR1, HC-FR2, HC-FR3 and HC-FR4 interposed between the HVRs, thus forming a sequence of the formula:
(HC-FR1)-(HVR-H1)-(HC-FR2)-(HVR-H2)-(HC-FR3)-(HVR-H3)-(HC-FR4).

### Claim 97 (depends on 96)

The method of claim 96, wherein one or more of the heavy chain framework sequences is selected from:
(a)
(SEQ ID NO: 4)
HC-FR1 is EVQLLESGGGLVQPGGSLRLSCAASGFTFS;
(b)
(SEQ ID NO: 5)
HC-FR2 is WVRQAPGKGLEWVS;
(c)
(SEQ ID NO: 6)
HC-FR3 is RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR;
or
(d)
(SEQ ID NO: 7)
HC-FR4 is WGQGTLVTVSS.

### Claim 98 (depends on 94)

The method of claim 94, wherein the light chain variable region comprises HVR-L1, HVR-L2 and HVR-L3 sequences, wherein:
(a)
(SEQ ID NO: 8)
the HVR-L1 sequence is TGTX7X8DVGX9YNYVS;
(b)
(SEQ ID NO: 9)
the HVR-L2 sequence is X10VX11X12RPS;
and
(c)
(SEQ ID NO: 10)
the HVR-L3 sequence is SSX13TX14X15X16X17RV;
and further wherein:
X7 is N or S;
X8 is T, R or S;
X9 is A or G;
X10 is E or D;
X11 is I, N or S;
X12 is D, H or N;
X13 is F or Y;
X14 is N or S;
X15 is R, T or S;
X16 is G or S; and
X17 is I or T.

### Claim 99 (depends on 98)

The method of claim 98, wherein:
(a) X7 is N or S; X8 is T, R or S; X9 is A or G; X10 is E or D; X11 is N or S; X12 is N; X13 is F or Y; X14 is S; X15 is S; X16 is G or S; and X17 is T; or
(b) X7 is S; X8 is S; X9 is G; X10 is D; X11 is S; X12 is N; X13 is Y; X14 is S; X15 is S; X16 is S; and X17 is T.

### Claim 100 (depends on 98)

The method of claim 98, wherein the light chain variable region comprises light chain framework sequences LC-FR1, LC-FR2, LC-FR3 and LC-FR4, interposed between the HVRs, thus forming a sequence of the formula:
(LC-FR1)-(HVR-L1)-(LC-FR2)-(HVR-L2)-(LC-FR3)-(HVR-L3)-(LC-FR4).

### Claim 101 (depends on 100)

The method of claim 100, wherein one or more of the light chain framework sequences is selected from:
(a)
(SEQ ID NO: 11)
LC-FR1 is QSALTQPASVSGSPGQSITISC;
(b)
(SEQ ID NO: 12)
LC-FR2 is WYQQHPGKAPKLMIY;
(c)
(SEQ ID NO: 13)
LC-FR3 is GVSNRFSGSKSGNTASLTISGLQAEDEADYYC;
or
(d)
(SEQ ID NO: 14)
LC-FR4 is FGTGTKVTVL.

### Claim 102 (depends on 98)

The method of claim 98, wherein the anti-PD-L1 antibody or antigen binding fragment thereof further comprises a human or murine constant region.

### Claim 103 (depends on 98)

The method of claim 98, wherein the antibody binds to human, mouse, or cynomolgus monkey PD-L1, or wherein the antibody is capable of blocking the interaction between human, mouse, or cynomolgus monkey PD-L1 and the respective human, mouse, or cynomolgus monkey PD-1 receptors.

### Claim 104 (depends on 94)

The method of claim 94, wherein:
(a) the heavy chain variable region comprises the sequence:
(SEQ ID NO: 24)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSS
IYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIK
LGTVTTVDYWGQGTLVTVSS;
and
(b) the light chain variable region comprises the sequence:
(SEQ ID NO: 25)
QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMI
YDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRV
FGTGTKVTVL.

### Claim 105 (depends on 76)

The method of claim 76, wherein the anti-PD-L1 antibody comprises:
(a) a heavy chain variable region (VH) comprising an HVR-H1, HVR-H2 and HVR-H3 of SEQ ID NO: 32; and
(b) a light chain variable region (VL) comprising an HVR-L1, HVR-L2 and HVR-L3 of SEQ ID NO: 33.

### Claim 106 (depends on 105)

The method of claim 105, wherein the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 15, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 16, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 17, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 18, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 19, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 20.

### Claim 107 (depends on 105)

The method of claim 105, wherein the anti-PD-L1 antibody comprises:
(a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 32, or the amino acid sequence of SEQ ID NO: 32 without the C-terminal lysine; and
(b) a light chain comprising the amino acid sequence of SEQ ID NO: 33.

### Claim 108 (depends on 105)

The method of claim 105, wherein each HVR is defined in accordance with the Kabat definition, the Chothia definition, a combination of the Kabat definition and the Chothia definition, the AbM definition, or the contact definition of HVR.

### Claim 109 (depends on 76)

The method of claim 76, wherein the cancer is selected from the group consisting of: breast, lung, colon, ovarian, melanoma, bladder, kidney, liver, salivary, stomach, gliomas, thyroid, thymic, epithelial, head and neck cancers, gastric and pancreatic cancer.

### Claim 110 (depends on 76)

The method of claim 76, further comprising the administration of at least one further therapeutic agent or vaccine.

### Claim 111 (depends on 110)

The method of claim 110, wherein the further therapeutic agent is cyclophosphamide and the vaccine is Stimuvax.

### Claim 112 (depends on 110)

The method of claim 110, wherein the further therapeutic agent is a chemotherapeutic agent.

### Claim 113 (depends on 112)

The method of claim 112, wherein the chemotherapeutic agent is gemcitabine.

### Claim 114 (depends on 112)

The method of claim 112, wherein the chemotherapeutic agent is cyclophosphamide.

### Claim 115 (depends on 112)

The method of claim 112, wherein the chemotherapeutic agents are 5-fluorouracil and oxaliplatin.

### Claim 116 (depends on 76)

The method of claim 76, wherein the method further comprises the application of a treatment regimen selected from the group consisting of: surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, hormonal therapy, angiogenesis inhibition and palliative care.

### Claim 117 (depends on 116)

The method of claim 116, wherein the treatment regime is radiation therapy.
